Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer
To investigate the clinical efficacy and safety of envollizumab combined with fruquintinib and SOX versus SOX in conversion therapy for patients with Her-2 negative, unresectable locally advanced gastric cancer.
Gastric Cancer
DRUG: Envolimab|DRUG: Fruquintinib|DRUG: Oxaliplatin|DRUG: Tegafur
Surgical conversion rate, Defined as the proportion of patients who have undergone surgical resection after multidisciplinary assessment after completing 4-6 cycles of conversion therapy, 2-3 months
Pathological complete response (pCR), Measured as the proportion of participants with a pathological complete response at the time of definitive surgery., 4 months|Median disease free survival (DFS) time, The time from opreation to the time when only 50% of the individuals had no relapse or tumor progression, 3 years|1-year DFS rate, 1 year|3-year DFS rate, 3 years|Objective response rate (ORR), Defined as the percentage of the participants in the analysis population who had a confirmed patial response and complete reponse according to RECIST 1.1 based on investigator assessment, 4 months|Major pathological response rate (MPR), The proportion of participants with a major pathological response (mPR) at the time of definitive surgery., 4 months|R0 resection rate, Defined as no residue under the microscope after resection, 2-3 month|Median survival time, The time from enrollment to the time when only 50% of the individuals alive, 3 years|Adverse event (AEs), Toxicity according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. The number of Participants with adverse events will be recorded at each treatment visit., 2 years|Quality of life (QOL), The quality of life of patients during treatment is eveluated by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 (V3.0), 2 years
To investigate the clinical efficacy and safety of envollizumab combined with fruquintinib and SOX versus SOX in conversion therapy for patients with Her-2 negative, unresectable locally advanced gastric cancer.